ArticleTranslational cancer research2019

Addition of atezolizumab to nab-paclitaxel plus carboplatin is a new standard option for the first-line treatment for non-squamous non-small cell lung cancer.

Teppei Yamaguchi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.